Cardiovascular diseases are still one of the diseases that lead to high mortality. Currently, drugs for preventing and treating cardiovascular diseases can significantly improve symptoms, but there are still shortcomings in reducing mortality rates. Therefore, new drugs that can improve symptoms and reduce mortality are needed. As a kind of hydroxylase inhibitor, roxadustat can effectively improve the symptoms of hypoxia by regulating the expression of hypoxia inducible factor (HIF). HIF is involved in almost all developmental, pathological or physiological processes in the body, including erythropoietin production, iron uptake, and metablism, cellular differentiation, energy metablism, inflammation and immune regulation. At present, the drug has a good prospect in the treatment of renal anemia, but it is rarely used in cardiovascular diseases. In this paper, the effects of roxadustat on cardiovascular diseases were systematically and comprehensively discussed, and some help was provided for the treatment of cardiovascular diseases.